This study is for women with ovarian or endometrial cancer. The purpose of the study is to see if the chance of ovarian or endometrial cancer growing can be lowered.
This clinical trial hopes to test the safety and effectiveness of the study drug, pembrolizumab (MK-3475), in combination with chemotherapy, and if this combination will improve survival in women with persistent, recurrent, or metastatic cervical cancer. You may be able to join this study if you are a female at least 18 years of age with persistent, recurrent, or metastatic cervical cancer and have not been treated with systemic chemotherapy, other than chemotherapy that was received with radiation. Participation will be based on specific criteria.
The study duration is estimated at about 2 years, and in some cases may be longer.
This study is for women who have ovarian cancer, fallopian tube cancer or primary peritoneal cancer which has grown or recurred. The purpose of this study is to compare any good and bad effects of adding Atezolizumab to the usual chemotherapy (liposomal doxorubicin) and to the usual chemotherapy with bevacizumab. Atezolizumab is a PD-L1 inhibitor that may allow the immune system to recognize and destroy tumor cells.
This study is for adult women who have advanced or recurrent endometrial (uterine) cancer. The purpose is to find out if the drug combination of paclitaxel, carboplatin and metformin works better than paclitaxel and carboplatin alone in treating uterine cancer.